UroGen Pharma Ltd.
NASDAQTotal Valuation
UroGen Pharma Ltd. carries a market capitalization of 2.15B, placing it among publicly traded companies globally. Its enterprise value stands at 1.88B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.15B |
| Enterprise Value | 1.88B |
Share Statistics
UroGen Pharma Ltd. currently has 48.72M shares outstanding.
| Shares Outstanding | 48.72M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 9.64, and the price-to-book ratio stands at -13.54.
| PE Ratio | N/A |
| PS Ratio | 9.64 |
| PB Ratio | -13.54 |
| P/TBV Ratio | -13.54 |
| P/FCF Ratio | -11.47 |
| P/OCF Ratio | -11.45 |
Enterprise Valuation
| EV / Sales | 9.97 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
UroGen Pharma Ltd. maintains a current ratio of 3.80, meaning it holds 3.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -148.14, indicating conservative leverage, while an interest coverage ratio of -3.95 demonstrates limited ability to service its debt obligations.
| Current Ratio | 3.80 |
| Quick Ratio | 3.18 |
| Debt / Equity | -148.14 |
| Debt / EBITDA | -3.06 |
| Interest Coverage | -3.95 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -42.33 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.09 |
Taxes
| Income Tax | -472,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
UroGen Pharma Ltd.'s stock has gained approximately 133.52754% over the past 52 weeks. The 50-day moving average sits at 42.65, while the 200-day moving average is 28.27.
| Beta (5Y) | N/A |
| 52-Week Price Change | 133.52754% |
| 50-Day Moving Average | 42.65 |
| 200-Day Moving Average | 28.27 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, UroGen Pharma Ltd. generated 188.73M in revenue and converted that into -97.64M in net income, yielding earnings per share of -1.97. EBITDA reached -64.01M, while operating income came in at -66.65M.
| Revenue | 188.73M |
| Gross Profit | 171.46M |
| Operating Income | -66.65M |
| Pretax Income | -98.11M |
| Net Income | -97.64M |
| EBITDA | -64.01M |
| EBIT | -66.65M |
| Earnings Per Share (EPS) | -1.97 |
Balance Sheet
UroGen Pharma Ltd. holds 107.98M in cash and equivalents against 196.13M in total debt, resulting in a net debt position of 109.60M. Total book value stands at -132.40M, with working capital of 173.51M providing operational flexibility.
| Cash & Cash Equivalents | 107.98M |
| Total Debt | 196.13M |
| Net Debt | 109.60M |
| Equity (Book Value) | -132.40M |
| Book Value Per Share | -2.72 |
| Working Capital | 173.51M |
Cash Flow
UroGen Pharma Ltd. produced -158.92M in operating cash flow over the past twelve months. After subtracting -218,000.00 in capital expenditures, free cash flow totaled -159.13M - equivalent to -3.22 per share.
| Operating Cash Flow | -158.92M |
| Capital Expenditures | -218,000.00 |
| Free Cash Flow | -159.13M |
| FCF Per Share | -3.22 |
Margins
UroGen Pharma Ltd. operates with a gross margin of 90.85, reflecting its pricing power and cost economics. The operating margin of -35.32 and net profit margin of -51.73 provide insight into operational efficiency.
| Gross Margin | 90.85 |
| Operating Margin | -35.32 |
| Pretax Margin | -51.98 |
| Profit Margin | -51.73 |
| EBITDA Margin | -33.92 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -5.87 |
| FCF Yield | -8.72 |
Scores
UroGen Pharma Ltd. posts an Altman Z-Score of -2.03, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -2.03 |